Satellos Bioscience (NASDAQ:MSLE) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Satellos Bioscience (NASDAQ:MSLE) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning.

Other equities analysts have also recently issued research reports about the company. Guggenheim assumed coverage on Satellos Bioscience in a report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price target for the company. Leerink Partners assumed coverage on Satellos Bioscience in a report on Monday, April 6th. They issued an “outperform” rating and a $20.00 price target for the company. Cantor Fitzgerald assumed coverage on Satellos Bioscience in a report on Wednesday, March 11th. They issued an “overweight” rating for the company. HC Wainwright upped their price target on Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Satellos Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Satellos Bioscience Stock Down 2.2%

Shares of NASDAQ:MSLE opened at $7.01 on Friday. Satellos Bioscience has a 1 year low of $4.53 and a 1 year high of $13.39. The stock has a market cap of $146.02 million, a PE ratio of -4.38 and a beta of 1.60. The business’s 50-day moving average price is $7.52.

Satellos Bioscience (NASDAQ:MSLE) last issued its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). Research analysts expect that Satellos Bioscience will post -2.29 EPS for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.